About our research group/lab
Our research group optimizes the prostate cancer patient journey from prevention and early detection towards treatment of primary and recurrent disease. The issues involved are organizing and financing concentration of diagnostics and care within regional and international networks, technological improvement and assessment of surgical intervention and diagnostics, building data exchange facilities, validation and valorization of molecular diagnostics, biobanking, home based technology, public support and patient empowerment. Our stakeholders include insurance companies, medical institutes, technical and transport industries, grant agencies, health professional and patient organizations.
- PRIAS study on active surveillance of indolent prostate cancer, including international validation by the Movember Global Action Plan 3 consortium.
- PIONEER: European network of excellence for big data in prostate cancer.
A complete overview of publications can be found here:
Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
Van Leenders GJLH, Kweldam CF, Hollemans E, Kümmerlin IP, Nieboer D, Verhoef EI, Remmers S, Incrocci L, Bangma CH, van der Kwast TH, Roobol MJ. (2019). Eur Urol 2019, pii: S0302-2838(19)30612-8.
Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease.
Schoots IG, Osses DF, Drost FH, Verbeek JFM, Remmers S, van Leenders GJLH, Bangma CH, Roobol MJ. (2018). Transl Androl Urol 2018;7:132-44.
A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Bokhorst LP, Valdagni R, Rannikko A, Kakehi Y, Pickles T, Bangma CH, Roobol MJ. PRIAS study group. (2016). Eur Urol 2016;70:954-60.
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A; ERSPC Investigators. (2014). Lancet 2014;384:2027-35.
Prostate-cancer mortality at 11 years of follow-up.
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators. (2012). N Engl J Med. 2012 Mar 15;366(11):981-90.
Collaboration within Erasmus MC
- Department of Pathology
- Department of Radiology
- Department of Clinical Chemistry
- Department of Medical Oncology
- Department of Genetics
Funding & Grants
- Innovative Medicine Initiative 2 consortium grant PIONEER - Prostate cancer diagnosis and treatment enhancement through the power of big data in Europe (partner C. Bangma)
- Achmea and CZ health insurers grant for Anser prostate cancer network to set up prostate cancer management and innovation in eight regional prostate centres in South West Netherlands (coordinator C. Bangma)
- Dutch Cancer Society-STW Technology for Oncology consortium grant ProVision - Visual Technology integrating quantitative patient outcomes to support multidisciplinary clinical decision making (coordinator C. Bangma)
- Movember Global Action Plan 3 (GAP3) on Active Surveillance for Prostate Cancer (PIs C. Bangma & M. Roobol)